ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Rheum

Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

Kurt Ullman  |  December 17, 2018

Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The…

VA Study Tracks Biologics Usage, Finds Dramatic Patient-Age Difference

Catherine Kolonko  |  December 17, 2018

Patients under the care of the U.S. Veterans Affairs who were older, non-white and had more comorbidities were less frequently given biologic initiation therapy to treat their rheumatoid arthritis (RA), according to a recent study. Researchers sought to identify predictors of greater use of biologic therapies, as well as factors associated with persistent use of…

The ACR & Rheumatology Research Foundation Are Transforming Our Specialty

Paula Marchetta, MD, MBA, & Abby Abelson, MD, FACR  |  December 17, 2018

The ACR and the Rheumatology Research Foundation have a rich history of collaboration and significant achievement. In many ways, our collaboration has become the classic triple threat of medicine, as we endeavor to support research, advance clinical care and expand education in so many intertwined and inseparable ways. Although we are greatly encouraged by the…

Big Data Drives New Research

Susan Bernstein  |  December 12, 2018

Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…

Low Muscle Density & Physical Function in Patients with RA

Arthritis Care & Research  |  December 4, 2018

Low muscle density due to the accumulation of intramuscular fat has been observed in RA patients and is associated with higher disease activity. New research sought to understand the relationship between muscle density, physical function and strength independent of body composition, including such factors as total and visceral adiposity. The results: Compared with healthy controls, low muscle density in RA patients was associated with low muscle mass, excess adiposity and greater disability…

Rheumatology Research Foundation Launches $75M Fundraising Push

From the College  |  November 19, 2018

The Rheumatology Research Foundation has embarked on its third and most ambitious fundraising campaign, with a goal of raising $75 million. The Leading Boldly: Transforming Rheumatology campaign will support Foundation programs to recruit the best and brightest into the field, train rheumatology health professionals at all career stages and support investigators conducting research that will…

Sputum Antibody Response in People at Risk for RA

Catherine Kolonko  |  November 19, 2018

Researchers say a study of individual antibody response to citrullinated and non-citrullinated proteins in sputum samples further supports the importance of the lung in early development of rheumatoid arthritis-related autoimmunity. Investigation of the fundamental mechanism that leads to antibody responses in rheumatoid arthritis is key to uncovering ways to predict and prevent the development of…

Pediatric Lupus Outcomes: Researchers Follow Kids into Adulthood

Linda Childers  |  November 19, 2018

A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…

The Burden of Rheumatic Diseases Among Indigenous People in Latin America Is Disproportionate

David C. Holzman  |  November 19, 2018

Indigenous communities in Latin America lack good healthcare—and often lack any healthcare—for musculoskeletal and rheumatic diseases.1 Global health initiatives tend to focus on infectious disease, despite the increasing rate of chronic diseases. In a survey of 6,155 individuals from eight indigenous communities, conducted by a team of Latin American investigators, the prevalence of these conditions…

Identifying Cardiovascular Risk Factors in Psoriatic Arthritis

Larry Beresford  |  November 19, 2018

Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardio­vascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…

  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 129
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences